Table 1.
Data from SITE studies on efficacy of steroid-sparing immunosuppressive agents in the treatment of non-infectious uveitis (adapted with permission from references 7–10).
| Azathioprine | MMF | MXT | CsA | Chi-Square+ | |
|---|---|---|---|---|---|
|
Age (Median) [ranqe in years] |
50.6 [9.2–86.4] |
47.1 [8.1–84.2] |
46.9 [0.4–93.5] |
36.1 [5.5–81.5] |
|
| Female (%) | 67.6 | 63.6 | 72.9 | 62.7 | 0.0153 |
| Caucasian (%) | 76.6 | 66.9 | 73.2 | 73.7 | 0.157 |
| # of patients (n)* | 145 | 236 | 384 | 373 | |
|
Complete control at 6/12 months (%) |
|||||
| - Total | 40.8/62.2 | 53.1/73.1 | 49.4/66.0 | 33.4/51.9 | <0.0001/<0.0001 |
| -Anterior | 23.7/34.6 | 55.2/72.4 | 55.6/67.2 | 30.4/54.3 | <0.0001/<0.0001 |
| - Intermediate | 69.3/89.8 | 65.0/76.7 | 47.4/74.9 | 39.3/51.8 | <0.0001/<0.0001 |
| - Posterior/Pan | 44.2/59.7 | 50.6/70.9 | 38.6/52.1 | 29.2/51.7 | <0.0001/<0.0001 |
|
Inactive or slightly active at 6/12 months (%) |
|||||
| - Total | 56.8/72.7 | 77.5/91.2 | 62.8/74.3 | 60.8/76.4 | <0.0001/<0.0001 |
| -Anterior | 28.2/42.6 | 84.9/100 | 69.7/71.6 | 52.8/85.8 | <0.0001/<0.0001 |
| - Intermediate | 87.5/100 | 83.1/100 | 62.8/89.4 | 73.7/80.2 | <0.0001/<0.0001 |
| - Pan/Posterior | 72.0/83.2 | 86.5/93.2 | 53.9/66.2 | 56.6/75.2 | <0.0001/<0.0001 |
|
Steroid-sparing success at 6/12 months (%) |
|||||
| Total | |||||
| - Prednisone | 32.2/46.9 | 40.7/55.0 | 37.3/58.4 | 22.1/36.1 | <0.0001/<0.0001 |
| ⩽10mg | 20.6/40.6 | 27.3/43.7 | 32.6/52.9 | 18.1/30.0 | <0.0001/<0.0001 |
| - Prednisone ⩽5mg | 05.2/09.5 | 04.4/12.1 | 05.1/18.8 | 03.6/08.2 | 0.629/0.0002 |
| - Off prednisone | |||||
| Anterior (n) | 21 | 48 | 126 | 75 | |
| - Prednisone | 16.6/24.9 | 47.2/53.1 | 46.1/62.6 | 28.5/42.4 | 0.0038/0.0017 |
| ⩽10mg | 11.5/19.5 | 46.4/51.3 | 41.8/59.4 | 26.9/40.4 | 0.0041/0.0013 |
| - Prednisone ⩽5mg | 00.0/08.3 | 05.8/18.4 | 06.2/17.6 | 08.8/14.9 | 0.61^/0.756 |
| - Off prednisone | |||||
| Intermediate (n) | 18 | 28 | 38 | 99 | |
| - Prednisone | 47.0/68.2 | 39.0/49.2 | 41.3/68.8 | 24.1/38.0 | 0.0915/0.0060 |
| ⩽10mg | 29.9/64.9 | 26.0/43.6 | 31.8/57.0 | 19.0/32.5 | 0.454/0.0068 |
| - Prednisone ⩽5mg |
00.0/00.0 | 00.0/13.8 | 07.4/15.0 | 03.7/09.2 | 0.443^/0.264^ |
| - Off prednisone | |||||
| Posterior/Pan (n) | 52 | 94 | 82 | 171 | |
| - Prednisone | 36.3/44.0 | 41.2/60.3 | 20.7/39.1 | 16.2/32.3 | <0.0001/0.0001 |
| ⩽10mg | 16.6/42.9 | 21.3/41.7 | 20.2/32.0 | 12.7/23.6 | 0.251/0.0064 |
| - Prednisone ⩽5mg | 07.1/09.9 | 02.6/09.1 | 03.0/11.9 | 00.7/03.9 | 0.0259^/0.105 |
| - Off prednisone |
MMF, mycophenolate mofetil; MXT, methotrexate; CsA, cyclosporine A; D/c, discontinued; SE, side effects; GI, gastrointestinal; HTN, hypertension
+
p values calculated by comparison of proportions unless noted otherwise.
*
Total # of patients includes patients with scleritis, ocular cicatricial pemphigoid, and other ocular inflammatory diseases not otherwise included in this table.
^
p value calculated by Fisher’s exact test because of small sample size.